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Abstract: We examined the hypothesis that hypoxic chemotransduction with stabilization of HIF-1 and activation of 
purinoceptors stimulate the endogenous NO production in the rat carotid body. The effects of blockade of purinoceptors 
with suramin, or blockade of HIF-1 hydroxylation by suppressing prolyl hydroxylase (PAH) activity on the endogenous 
NO release measured electrochemically by microsensor inserted into the isolated carotid body superfused with bicarbon-
ate-buffer were examined. Suramin did not change the resting NO level under normoxic conditions but it significantly de-
creased the hypoxia-induced NO elevation in a dose-dependent manner. Suramin (100μM) blocked the NO response to 
acute hypoxia by 53%. Intracellular iron chelator, ciclopirox olamine (CPX) significantly increased the resting NO release 
close to the hypoxic level, which was reversed by FeSO4 or blocked by L-NMMA. Also, PAH inhibition with dimethy-
loxalylglycine (DMOG) moderately increased the resting NO release. In the presence of CPX and DMOG the resting NO 
release was increased to the hypoxic level. Collectively, results suggest that iron chelation and purinoceptor stimulation 
play a role in the hypoxic chemotransduction for an increase in the endogenous NO production in the rat carotid body. 
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INTRODUCTION 
  Hypoxic chemotransduction of the carotid body is central 
to the regulation of cardiorespiratory performance by the 
carotid chemoreflex. Type-I glomus cells in the carotid body 
are believed to be the oxygen-sensitive sites for the chemo-
transduction [1]. In addition to the membrane-limited 
mechanism with modulation of potassium channel activities 
by hypoxia [2, 3], recent evidence support an involvement of 
stabilization of hypoxia-inducible factor (HIF)-1 in the che-
motransduction [4]. HIF-1 is a heterodimeric complex con-
sists of two subunits. The protein level of HIF-1 subunit is 
post-transcriptionally regulated by prolyl and asparaginyl 
hydroxylase (PAH) activity for the HIF-1 hydroxylation in 
the presence of oxygen for the proteasomal degradation of 
HIF-1 with ubiquitylation [5, 6]. The HIF-1 subunit is 
constitutively expressed independent of oxygen level. Deple-
tion of cofactors required for the PAH activity, physiologi-
cally by hypoxia or pharmacologically by intracellular iron 
chelation, increases the HIF-1 protein level in the carotid 
body [7-9]. In addition, oxoglutarate analogue suppresses 
PAH activity and increases endogenous HIF-1 level [10]. 
Roy et al. [11] reported that intracellular iron chelator, ci-
clopirox olamine (CPX) inhibits potassium currents and in-
creases cytosolic calcium level in rat glomus cells with in-
creased carotid chemoreceptor activity. 
  In addition to catecholamines [1, 12], recent studies sug-
gest ATP, which is co-released with acetylcholine, as a puta-
tive neurotransmitter involved in the chemotransduction [13, 
14]. Purinergic transmission is indicative because of the ex-
pression of purinoceptor subunits P2X2 and P2X3 in the 
nerve fibers co-localized with glomus clusters containing   
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tyrosine hydroxylase [15]. Importantly, ATP excited petrosal 
neurons via ionotropic P2X receptor [16]. Also, P2X purino-
ceptor suramin inhibited hypoxic transmission of the carotid 
body [16]. Thus activation of purinergic transmission plays a 
role in the chemotransduction. 
  The hypoxic response of the carotid body is modulated 
by nitric oxide (NO), presumably produced by NO synthase 
(NOS) located in nerve endings and vascular endothelium in 
the carotid body [17-22]. Hence, NOS inhibition enhances 
the hypoxic response of the carotid body despite minimal 
effects on the resting activity [23-25]. We have shown an 
increase in endogenous NO level in the rat carotid body in 
acute hypoxia, which is physiologically important to the in-
hibition of carotid chemoreceptor activity for a negative 
feedback control of the activity in hypoxia [26, 27]. At pre-
sent, there is a paucity of information on the physiological 
events between the chemotranduction and the endogenous 
NO release in the carotid body. It was hypothesized that hy-
poxic chemotranduction with stabilization of HIF-1 and acti-
vation of P2X/P2Y purinoceptors stimulate the endogenous 
NO production in the rat carotid body. Hence, the aims of 
the present study were to determine the effects of blockade 
of purinoceptors with suramin, or suppression of PAH activ-
ity with iron chelator CPX, and with the oxoglutarate ana-
logue dimethyloxalylglycine (DMOG), on the endogenous 
NO release produced in some intraglomic structure, probably 
chemoreceptor cells and efferent fibers. 
MATERIALS AND METHODOLOGY 
Isolation of the Carotid Body 
  The experimental protocol for this study was approved 
by the Committee on the Use of Live Animals in Teaching 
and Research of The University of Hong Kong. Following 
deep anesthesia with halothane, young adult Sprague-
Dawley rat (ca. 150-200 g) was decapitated and the carotid 
bifurcation was excised rapidly. The carotid body was care-2    The Open Biochemistry Journal, 2007, Volume 1  Fung et al. 
fully dissected free from the bifurcation in chilled rat 
Ringer’s solution oxygenated with 95% O2 and 5% CO2. The 
carotid body was then incubated in a tissue bath with colla-
genase (0.06%) and protease (0.02%) in oxygenated 
Ringer’s for 30 min at 35±1 °C. The carotid body was then 
held in the recording chamber at 35±1 °C, and superfused 
with oxygenated Ringer’s solution in a flow rate of 2 
ml/min. 
Nitric Oxide Electrode 
  The fabrication and calibration of the NO electrode has 
been described in previous reports [26-28]. Briefly, a labora-
tory-made Pt wire insulated in a poly-ethylene tube was 
dipped in Nafion. The Nafion-coated electrode was further 
modified with palladium and iridium oxide particles for im-
proving the sensitivity of the NO electrode. Then, a thin film 
of poly-o-aminophenol (POAP) was deposited in the outer 
layer to ameliorate the selectivity of the NO electrode and to 
avoid fouling by proteins. NO standards were prepared by 
serial dilution of a saturated NO solution. The saturated NO 
solution was prepared by bubbling phosphate buffered saline 
(pH 7.0) with pure N2 for 30 min to remove O2, following by 
NO gas (Matheson) for 30 min. Standards were made fresh 
for each experiment and kept in a glass flask with a rubber 
septum. Electrochemical experiments were performed on a 
CHI 660A Electrochemical Analyzer (CH Instruments, 
USA) at room temperature in a three compartment cell with 
a Ag/AgCl reference electrode, a Pt wire auxiliary electrode 
and a chemically modified electrode as working electrode. 
The NO electrode was calibrated with successive injections 
of various concentrations of NO from 20-1000 nM to the 
Ringer's solution in the recording chamber. The current was 
measured at a voltage of 0.85 V. The current response to 
various NO concentrations in nanomolar range was very 
close to linear with the coefficient of the linear equation (y = 
a + bx) not less than 0.95. The detection limit of our NO 
electrode was about 10 nM with signal to noise ratio of 3. 
The current responses to NO were comparable in Ringer’s 
solution gassed with 95% O2 / 5% CO2 or 95% N2 / 5% CO2 
in the presence or absence of dopamine (30 nM). The NO 
electrode responded to dopamine in micromolar (1 μM) but 
not in nanomolar concentration ranges (30 nM) and the cur-
rent response was more selective for NO than dopamine with 
a ratio of about 1:100. The current response of the NO elec-
trode was examined before and after the experiment. 
Experimental Paradigm 
  The electrode and carotid body were equilibrated in the 
perfusate for 15-30 min. The tip of the NO electrode was 
gently inserted into the carotid body under visual guidance 
with a dissecting microscope. Following current recording in 
the resting condition for 10-15 min, acute hypoxia was in-
duced for 5 min following by recovery for 20-30 min. Acute 
hypoxia was induced by switching the perfusate to Ringer’s 
solution gassed with 95% N2 and 5% CO2. To assess the 
involvement of HIF-1 and purinergic transmission, the ef-
fects of blockade of P2X/P2Y purinoceptors with suramin, 
or suppression of PAH activity with CPX, DMOG on the 
endogenous NO release in the superfused rat carotid body 
were examined. The effect of CPX can be reversed by FeSO4 
[11] and the endogenous NO production was blocked by 
non-selective NO synthase inhibitor N
G-Monomethyl-L-
arginine acetate (L-NMMA). For the drug treatment, L-
NMMA (100 μM) or suramin (10-100 μM) or CPX (5 μM) 
or DMOG (1 mM) or FeSO4 (200 μM) or catalase (1000 
unit/ml) or superoxide dismutase (600 unit/ml) was added 
freshly to the Ringer’s solution for the perfusion. 
Materials and Pharmacological Agents 
  The rat Ringer’s solution contained (mM): NaC1 125, 
KC1 3.1, NaHCO3 26, NaH2PO4 1.25, MgSO4 1.3, CaCl2 
2.4, D-Dextrose 10, pH at 7.35. K2IrCl6, K2PdCl6,  o-
Aminophenol and Nafion perfluorinated ion-exchange resin 
in alcohol were obtained from Aldrich. Chemicals were ob-
tained from Sigma. 
Data Analysis 
  For the measure of NO release, the resting and peak val-
ues of the current were subtracted and calibrated in NO con-
centration (nanomoles) according to the current response 
curve of the NO electrode. Values were normalized as a per-
centage of control if necessary and presented as mean+/-SE. 
Means were compared with Student t-test or the non-
parametric Wilcoxon signed-rank test. ANOVA with a post-
hoc test (Dunnett’s t-test) was used for multiple comparisons 
of values in studies among groups. Differences were consid-
ered significant at P<0.05. 
RESULTS 
  The resting NO level decreased gradually with the perfu-
sion of a non-selective NOS inhibitor L-NMMA (100μM) 
for 10 min under normoxic conditions (Fig. 1). On average, 
the endogenous NO release was reduced by 76.7+/-2.1nM 
(n=6) in the carotid body. However, perfusion of suramin 
(10-100μM) did not significantly reduce the resting NO re-
lease under normoxic conditions (Fig. 1). 
  The NO level rapidly elevated to a plateau level within 
minutes in acute hypoxia (Fig. 2). On average, the NO re-
lease was elevated by 174+/-2.3nM in the carotid body in 
hypoxia (n=10). Suramin (10-100μM) significantly de-
creased the hypoxia-induced NO elevation in a dose-
dependent manner (Fig. 2). On average, suramin at 100μM 
reduced the NO release to 82+/-3.4nM (n=6) and blocked the 
hypoxic response by about 53% (n=6). 
  The perfusion of CPX (5μM) alone at resting signifi-
cantly increased the NO level by 154.3+/-9.8nM (n=6), 
which was slightly lower than the level induced by hypoxia 
(Fig.  3). In addition, the CPX-induced NO elevation was 
significantly reversed by FeSO4 and was attenuated by L-
NMMA (Fig. 3). The effect of FeSO4 on the NO elevation 
was not altered by concomitant application of superoxide 
dismutase (n=5) or catalase (n=3) and the NO levels were 
fully recovered to the resting levels (Fig. 3). 
  During the perfusion of DMOG (1mM), the resting NO 
release was increased by 33.7+/-4.7nM (n=6), although the 
elevated NO level was significantly less than that induced by 
hypoxia (Fig. 4). DMOG increased the hypoxia-induced NO 
elevation and CPX significantly increased the NO release 
induced by DMOG (Fig. 4). 
DISCUSSION 
  This is the first study reporting an increase in endogenous 
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transmission in the carotid body. The major observations of 
this study are that: (1) iron chelation, which could block 
HIF-1 hydroxylation by suppressing PAH activity under 
normoxic conditions, closely mimic the effect of acute hy-
poxia on the NO production in the carotid body; (2) blockade 
of P2X and/or P2Y purinoceptors attenuated the effect of 
acute hypoxia on the NO production in the carotid body. 
Hence, CPX and DMOG rapidly elevated resting NO release 
in normoxia to levels comparable to the hypoxic level in the 
carotid body. In addition, suramin did not change the resting 
NO release under normoxic conditions but dose-dependently 
decreased the hypoxia-induced NO elevation in the carotid 
body. Taken together, these results suggest that iron chela-
tion and purinoceptor activation play a role in the hypoxic 
chemotransduction for an increase in the endogenous NO 
production in the rat carotid body. 
  In consistent with our previous reports [26, 27], the NO 
level elevated rapidly within a minute of hypoxia and it 
reached its peak level in 4-5 min of hypoxia when O2 con-
centration in the bath was reduced to its nadir (about 1 
mmHg). Then, the NO concentration decreased gradually 
back to the resting level during recovery to normoxia from 
hypoxia (Fig. 2). The fact that blockade of NOS activity de-
creased the basal level of NO and largely attenuated the re-
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Under normoxic conditions, perfusion of suramin did not significantly reduce the endogenous NO release measured electrochemi-
cally by microsensor inserted into the rat carotid body superfused with Ringer’s solution. Left panel shows the current tracings with suramin 
(10, 25, 50 and 100μM) or L-NMMA for 10 min. Vertical bar is the calibrated NO concentration. Right panel shows the summary of the 
data. The resting NO level was significantly reduced by L-NMMA but not by suramin (n=6-10 carotid bodies in each group). The dashed 
line depicts the virtual baseline for the measurement in a tracing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Perfusion of suramin significantly decreased the hypoxia-induced NO elevation. Left panel shows the current tracings in acute hy-
poxia (N2, bar 5 min) with or without the presence of suramin. Vertical bar is the calibrated NO concentration. Right panel shows the sum-
mary of the data. The NO level was significantly reduced by suramin in a dose-dependent manner (n=6-10 carotid bodies in each group). The 
dashed line depicts the virtual baseline for the measurement in a tracing. 4    The Open Biochemistry Journal, 2007, Volume 1  Fung et al. 
lease of NO in hypoxia, suggests that the endogenous NO 
production is specific to the NOS in the carotid body. 
  The observations that under normoxic conditions CPX 
and DMOG increased the endogenous NO level close to the 
level induced by acute hypoxia, indicate that HIF-1 activa-
tion may be involved in the endogenous NO release during 
acute hypoxia. Results lend support to the idea that HIF-1 
stabilization could play a role in the chemotransduction dur-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Perfusion of CPX significantly increased the resting NO release under normoxic conditions. Left panel shows the current tracings 
from top to bottom in acute hypoxia (N2, bar 5 min), in the presence of CPX followed by FeSO4 or by FeSO4 with superoxide dismutase 
(SOD) during resting or in the presence of L-NMMA. Vertical bar is the calibrated NO concentration. Right panel shows the summary of the 
data. The resting NO level was significantly increased by CPX to a level close to the level induced by hypoxia and the NO level was signifi-
cantly blocked by L-NMMA (n=6-10 carotid bodies in each group). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Perfusion of DMOG increased the resting NO release and the hypoxia-induced NO elevation. Left panel shows the current tracings 
from top to bottom in acute hypoxia (N2, bar 5 min), in the presence of DMOG during normoxia or hypoxia, in the presence of DMOG and 
CPX in normoxia. Vertical bar is the calibrated NO concentration. Right panel shows the summary of the data. The resting NO level was 
increased by DMOG but the level was significantly less than that induced by hypoxia. DMOG also increased the NO release during hypoxia. 
In the presence of CPX and DMOG the resting NO release was increased to the hypoxic level (n=6-10 carotid bodies in each group). Carotid body NO Release with HIF and Purinergic Activation  The Open Biochemistry Journal, 2007, Volume 1    5 
ing acute hypoxia. Neither the glomic structure nor the 
mechanisms underlying are known, but there are data sug-
gesting an activation of chemotransduction by HIF-1 in the 
chemosensitive cells. Hence, CPX increases the HIF-1 level 
and mimics the hypoxic effects on the potassium current, 
intracellular calcium level in the glomus cell and carotid 
chemoreceptor activity [7, 8, 11] as well as the NO release 
shown in this study. In addition, the CPX-induced NO eleva-
tion was normalized by iron supplement with FeSO4, which 
cannot be attributed to the generation of superoxide anion 
because superoxide dismutase or catalase did not altered the 
FeSO4 action. Moreover, suppression of PAH activity with 
DMOG also increased the resting NO release, despite a weak 
effect comparing with that of the CPX. In this context, it has 
been reported that DMOG alone had minor effect on HIF-1 
level under normoxic conditions but the effect was promi-
nent in ischemic conditions in the mouse skeletal muscle 
[10], which is consistent with the findings in this study. Yet, 
DMOG is a non-specific 2-oxoglutarate-dependent dioxy-
genase inhibitor that may have non-HIF targets [29]. Also, it 
has also been shown that inhibition of HIF hydroxylation in 
carotid body slices with 1 mM DMOG had no effect on the 
exocytotic response of the cell to hypoxia [30]. Thus, it is 
plausible that a separate mechanism may be mediated by iron 
chelation. Indeed, it has been proposed that Fenton reaction 
and free radicals may be involved in the hypoxic chemo-
transduction, which may be interfered by iron chelation [11, 
30]. 
  The observations that suramin did not change the resting 
NO level but dose-dependently attenuated the hypoxia-
induced NO elevation, suggest that activation of purinergic 
receptor is involved in the endogenous NO release during 
acute hypoxia. It is plausible that the NO production is in-
creased by activation of ionotropic purinoceptors localized at 
the nerve endings apposed to the glomus cells in the carotid 
body. Studies have shown the expression of purinoceptor 
subunits P2X2 and P2X3 in the nerve fibers co-localized 
with the glomus clusters [15, 31]. In addition, NOS is local-
ized in the nerve endings and plexus of nerve fibers in lob-
ules of parenchyma cells and near small blood vessels of the 
carotid body, which plays physiological role in the NO inhi-
bition of carotid chemoreceptor activity [25, 26, 32, 33]. 
  For the NO production by NOS, L-arginine, NADPH and 
O2 are co-substrates. It is generally accepted that concentra-
tions of L-arginine and NADPH are high in the tissues and 
are unlikely to be the limiting factor. Although the low level 
of O2 during hypoxia may reduce the NO synthesis in the 
catalytic reactions [34], it may not be the dominant factor in 
vivo because the residue amount of O2 in tissue during hy-
poxia may minimize the reduction in NO synthesis. In fact, it 
has been shown that NO concentration in brain tissue in-
creases during cerebral ischemia [35], suggesting the O2 is 
taken from the tissue for the conversion of L-arginine to N
-
hydroxyarginine. Thus, O2 concentration may not be the only 
factor that determines the amount of NO production in the 
carotid body during hypoxia. In addition, activation of NOS 
is driven by calcium-dependent mechanisms. Elevation of 
cytosolic calcium concentration to about 400 nM is required 
for the binding between calmodulin and the NOS, which is 
necessary for the enzyme to become fully active [36, 37]. 
During hypoxia, elevation of intracellular calcium in the 
chemosensitive glomus cell is essential for the chemotrans-
duction. In fact, a recent study has demonstrated morpho-
logical evidence supporting an increase in NO production in 
the glomus cell during acute hypoxia [38]. Thus, the NO 
released by the glomus cell could contribute to the hypoxia-
induced NO elevation in the carotid body. In fact, increased 
HIF-1 level by iron chelators or PAH suppression has been 
shown to mimic the hypoxic effects on the potassium cur-
rent, intracellular calcium level in the glomus cell and ca-
rotid chemoreceptor activity [7, 8, 11]. 
  Moreover, increased autonomic efferent activity may be 
associated with an increase of cytosolic calcium concentra-
tion in the nNOS-containing efferent nerve fibers for the NO 
release in the carotid body. In this context, Campanucci et al. 
[39] recently reported that P2X receptors are localized to the 
efferent nerve endings and activation of these receptors by 
ATP could lead to an inhibition of chemoreceptor activities 
via an NO mechanism. Furthermore, P2X receptors are also 
localized to the afferent nerve endings apposed to the glomus 
cluster [31]. Thus, an increase in afferent activity during 
hypoxia could cause the calcium influx stimulating the NO 
production. We cannot rule out the NO released from the 
blood vessels given the fact that P2X receptors is expressed 
in endothelial cells [40, 41], although it is not clear the ex-
tracellular ATP levels and the contribution of the endothelial 
P2X receptors to the NO elevation under hypoxic conditions. 
Thus, it is likely that there are multiple sources of NO, which 
could contribute to the control of the chemoreceptor activity. 
  It is well known that NO inhibits carotid chemoreceptor 
activity during hypoxia [23-25]. The increase in endogenous 
NO level in the rat carotid body in acute hypoxia is physio-
logically important to the negative feedback control of the 
carotid chemoreceptor activity in hypoxia [26, 27]. In fact, 
NO inhibits L-type voltage-gated calcium channels in 
glomus cells [42], and this could reduce the calcium entry, 
excitability and neurotransmitter release of the glomus cells 
during hypoxia. It is plausible that the elevated NO level 
could serve as a negative modulator to regulate the ATP re-
lease during acute hypoxia. In addition, it has been reported 
that NO can modulate the level of HIF-1 [43] via the phos-
phatidylinositol 3-kinase pathway [44] or by inhibiting the 
activity of prolyl hydroxylases under normoxic or hypoxic 
conditions [45]. Thus, NO could also be an important modu-
lator regulating the HIF-1 level and HIF-1 activation in the 
carotid body. 
  In conclusion, iron chelation, which could suppress the 
PAH activity for HIF-1 hydroxylation under normoxic con-
ditions, closely mimic the endogenous NO production in the 
carotid body during acute hypoxia. In addition, the hypoxia-
induced NO production was reduced by blockade of 
P2X/P2Y purinoceptors in the carotid body. Thus, these re-
sults support that iron chelation and activation of purinocep-
tors play a role in the hypoxic chemotransduction for an in-
crease in the endogenous NO production in the rat carotid 
body. 
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